AbCelex Technologies nets $2 mln in Series A round led by Cultivian Sandbox
Canadian biotechnology company AbCelex Technologies Inc has secured $2 million in a Series A financing round. The round was led by U.S. venture capital firm Cultivian Sandbox Ventures, which is focused on investing in agriculture and industrial biotechnology sectors. Investment proceeds will be used to support research and development of AbCelex's antibody-based approach to controlling pathogens in farm animals that are related to food-borne illnesses. Concurrent with the deal, Ron Meeusen and Matthew Bell of Cultivian Sandbox have joined the company's board of directors. Founded in 2010, AbCelex is based in Toronto.
28 April 2014•5 mins read
